Cibus Inc. Class A (CBUS)
NASDAQ: CBUSHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
CBUS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $123.81M
- EPS (TTM)
- -$1.65
- Dividend yield
- None
- 52-week range
- 1.09 – 4.19
- Day range
- 1.50 – 1.64
- Volume / Avg
- 99.21K / 208.04K
- Beta
- —
- Shares outstanding
- 76.43M
52-week range
CBUS stock today
On Oct 7, CBUS ended the session at $1.62, adding $0.05 (3.18%), versus the S&P 500's 0.22% decline. Trading was light, with 99.21K shares changing hands, about 48% of the average daily volume. Shares are 61.3% below their 52-week high of $4.19, set on Mar 11, 2026 and 48.6% above the 52-week low of $1.09, near the bottom of the past year's range.
CBUS is down 6.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 13.3%. Cibus has posted a net loss over the last twelve months (EPS of -$1.65), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cibus
Company profileCibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Craig Wichner
- Headquarters
- San Diego, CA
- Employees
- 118
- IPO year
- 2017
- Website
- cibus.com
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$14.33+784.57%
- Strong buy 0
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Cibus peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FHTXFoghorn Therapeutics Inc. | 2.09 | +6.09% | $124.12M | vs CBUS |
| VTVTvTv Therapeutics Inc. Class A | 31.01 | +3.26% | $122.61M | vs CBUS |
| SEERSeer Inc. Class A | 2.21 | +0.91% | $122.37M | vs CBUS |
| NRXPNRX Pharmaceuticals Inc. | 2.90 | -1.36% | $125.56M | vs CBUS |
| HURATuHURA Biosciences Inc. | 1.98 | +1.54% | $126.18M | vs CBUS |
| SPRBSpruce Biosciences Inc. | 44.40 | +3.77% | $127.61M | vs CBUS |
| TNYATenaya Therapeutics Inc. | 0.5334 | -2.40% | $119.60M | vs CBUS |
| TNXPTonix Pharmaceuticals Holding Corp. | 7.55 | -1.88% | $129.49M | vs CBUS |
Indexes, lists and sector
Appears in lists
Cibus stock FAQ
What is Cibus's stock price today?
CBUS last traded at $1.62 as of Oct 7, 4:00 PM EDT, up 3.18% on the day. Prices are delayed at least 15 minutes.
Does Cibus pay a dividend?
No. Cibus does not currently pay a regular cash dividend.
Who is Cibus's CEO?
Mr. Craig Wichner is the chief executive officer of Cibus Inc. Class A, which has about 118 employees.
Has CBUS ever split its stock?
Yes. The most recent CBUS stock split was a 1-for-5 split on Jun 1, 2023, one of 2 splits on record.
What is the CBUS 52-week high?
The 52-week high for CBUS is $4.19 and the 52-week low is $1.09. The stock is currently 61.3% below its high.